Medicijn voor de Maatschappij is a platform for sustainable and affordable availability of medicines for rare diseases. It is a knowledge platform and they carry out projects to make specific medicines available to patients for the long term. They also conduct research into the laws and regulations on medicines for rare diseases.

About

Patients need safe and effective treatment, even if it concerns a rare disease. This is only possible if medicines for rare diseases are available and can be supplied at a socially acceptable price. To achieve this, it is important that all parties involved (doctors, pharmacists, pharmaceutical companies, patients, etc.) join forces. Medicine for Society wants to promote this. Their goal: to keep medicines for rare diseases available and affordable by sharing knowledge, conducting research and realizing projects.

Read more

Research

They also work on (continued) availability of medicines for rare diseases through scientific research. They conduct research that contributes to new ideas and models for the availability of these medicines. In doing so, they opt for models in which (clinical) research is conducted as independently and transparently as possible. At the same time, they investigate how medicines for rare diseases can be used properly and safely.

Medicijn voor de Maatschappij

Medicijn voor de Maatschappij also conducts research into legislation and regulations (regulatory science) around medicines for rare diseases. By examining how the rules work out in practice, it becomes clear where the shoe pinches and opportunities for improvement are revealed.

Projects

Medicijn voor de Maatschappij carries out projects that contribute to the structural availability of medicines for rare diseases. Their projects vary from organizing a tender that leads to cost savings, to registering a medicine, to pharmacy preparation as a temporary solution.

Overview of the projects (Dutch)

    Team & researchers

    The team consists of experts from various disciplines.

      Take a look at the team

      Media (Dutch)

      This video is not available because you have not accepted our video cookies.

      Newspaper article in ZorgKrant: Door het Orphan Drug Access Protocol medicijn sneller beschikbaar (2022)

      Read the article

      Newspaper article in de Volkskrant: Een klinisch topdokter moet óók hoogleraar kunnen worden (2024)

      Read the article

      Contact

      Website of Medicijn voor de Maatschappij (in Dutch): www.medicijnvoordemaatschappij.nl

      Mary Duijnker (secretary): info@medicijnvoordemaatschappij.nl

      LinkedIn